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Abstract: Recent guidelines recommend consideration of genetic screening in all newly diag-
nosed patients with pheochromocytoma. Patients diagnosed with pheochromocytoma in the 
Region of Southern Denmark during 2006–2013 without previously recognized monogenetic 
etiology were offered genetic screening for mutations in the VHL, RET, SDHB, SDHC, and 
SDHD genes. A total of 41 patients were included, and genetic data were available in 35. In four 
of the 35 patients, a pathogenic variant was identified prior to the diagnosis of pheochromocy-
toma (von Hippel–Lindau disease, n=2; neurofibromatosis type 1, n=2). The patients carrying 
a genetic mutation were all younger than 45 years at time of diagnosis of pheochromocytoma, 
two patients presented with bilateral tumors, and one patient had a positive family history 
of pheochromocytoma. Genetic screening of the remaining 31 patients did not identify any 
mutations. The sporadic cases had a median age of 58 years (range 33–80 years). Three of 31 
sporadic cases (ages 60, 69, and 76 years at time of diagnosis) presented with bilateral adrenal 
tumors, one patient had multiple adrenal tumors in both adrenal glands, and no patients had a 
positive family history of pheochromocytoma. Of the 31 patients, 24 (68.6%) were diagnosed 
with pheochromocytoma due to evaluation of an adrenal incidentaloma. In conclusion, monoge-
netic etiology was identified in four of 35 (11.4%) patients diagnosed with pheochromocytoma.
Keywords: pheochromocytoma, genetic screening, guidelines, adrenal incidentaloma
Introduction
Pheochromocytomas are rare neuroendocrine catecholamine-secreting tumors arising 
from chromaffin cells in the adrenal medulla with an incidence of approximately two to 
ten per 1,000,000 per year.1 Diagnosis is based on elevated levels of plasma-fractionated 
metanephrines or urinary catecholamines.2 Pheochromocytomas are often sporadic, 
but 8%–24% are caused by germ-line mutations and most commonly associated with 
the NF1, VHL, RET, SDHA, SDHB, SDHC, and SDHD genes.3,4 The diagnosis of NF1 
and von Hippel–Lindau (VHL) disease is established in probands fulfilling the clinical 
criteria,5,6 and the diagnosis can be genetically verified in approximately 95% of cases.6,7
The prevalence of SDHC-mutation carriers is low, but they may develop all the stig-
mata of the disease.4 Additionally, patients with mutations of the SDHB gene demand 
special attention, because they have a high risk of malignant disease that reflects both 
the typically large sizes and extra-adrenal location of associated tumors.4
The main criteria for focused genetic evaluation include young age at diagnosis, 
bilateral/multiple tumors, or a positive family history with pheochromocytoma or 
tumor syndrome.8 Different algorithms have been applied to identify patients eligible 
for genetic screening.8 However, recent guidelines for pheochromocytomas and 
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paragangliomas recommend that genetic screening should 
be considered in all patients with pheochromocytoma, 
prioritizing young patients with positive family history or 
presence of multifocal or bilateral tumors.4 Identification 
of pathogenic genetic mutation in patients with pheochro-
mocytoma confirms the clinical diagnosis and allows for 
genetic counseling and predictive testing of family members. 
Subsequently, mutation-positive carriers may enter individual 
surveillance programs.
Pheochromocytoma may be diagnosed during the 
evaluation of an adrenal incidentaloma, which is defined 
as an adrenal mass discovered incidentally during imaging 
performed due to problems unrelated to adrenal disease.9 
The prevalence of adrenal incidentalomas is approximately 
4% and increases with age, and pheochromocytomas are 
reported to account for 8% of all adrenal incidentalomas.9,10 
To our knowledge, no studies have evaluated the impact of 
systematic genetic screening of pheochromocytomas diag-
nosed during the evaluation of adrenal incidentalomas. In the 
present retrospective cohort study, we evaluated the results 
of systematic genetic screening in patients newly diagnosed 
with pheochromocytoma and compared characteristics in 
patients with monogenetic etiology and patients with sporadic 
pheochromocytoma.
Materials and methods
Study eligibility
All patients referred to the Department of Endocrinology and 
Metabolism at Odense University Hospital in the Region of 
Southern Denmark during January 1, 2006, to December 
31, 2013, suspected of increased catecholamine secretion 
(n=108) (Figure 1) were screened for excessive hormonal 
secretion following current guidelines: patients with adrenal 
incidentaloma were screened with computed tomography 
of the adrenal glands and measurement of plasma-free 
metanephrines, 24-hour urinary cortisol or 1 mg overnight 
dexamethasone test, serum chromogranin A, and in patients 
with hypertension or hypokalemia, additionally plasma renin 
and aldosterone. As diagnostic tests for pheochromocytoma, 
we measured levels of either nightly urinary catecholamines 
or plasma metanephrines.
Criteria for inclusion in the present study were 1) bio-
chemical and anatomical presence of pheochromocytoma, 
and 2) patients who had undergone surgery with removal of 
tumor and/or adrenalectomy of an adrenal gland. Criteria for 
exclusion were 1) absence of intra-adrenal tumor, 2) para-
gangliomas explicitly, 3) extra-adrenal secreting chromaffin 
tumors, 4) nonsecreting head–neck paragangliomas, 5) no 
operation, and 6) patients with normal levels of both urinary 
catecholamines and plasma metanephrines. A total of 41 
patients fulfilled the inclusion criteria and were included 
in the study; 66 patients were excluded for one or more the 
aforementioned exclusion criteria. Documentation was not 
accessible in one patient.
The present study was an audit regarding treatment and 
follow-up of patients with pheochromocytoma. Patient infor-
mation in the present study was used in anonymous form. 
This was reviewed and verified by the legal department of 
Odense University Hospital.
Genetic screening program
All patients with pheochromocytoma and without previ-
ously recognized monogenetic etiology were offered genetic 
screening in the five genes included for the systematic genetic 
screening program in 2006–2013. VHL, RET, SDHB, SDHC, 
and SDHD were analyzed with sequencing of all coding 
Figure 1 Flowchart of study population.
Increased catecholamine secretion
(n=108)
Pheochromocytoma
(n=42)
No pheochromocytoma
(n=66)
No documentation
(n=1)
Unknown genetic status
(n=6)
Sporadic pheochromocytoma
(n=31)
Monogenetic etiology
(n=4)
Study population
(n=41)
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regions and subsequently analyzed for deletions and dupli-
cations. A diagnosis of multiple endocrine neoplasia type 1 
relied on clinical criteria.
Grouping of patients
Patients who underwent genetic screening were divided into 
sporadic or nonsporadic pheochromocytoma. Sporadic pheo-
chromocytoma was defined as 1) negative genetic screening 
result, 2) absence of family history of pheochromocytoma, 3) 
absence of metastatic disease, and 4) unilateral tumor. Three 
patients presented with bilateral tumors, but were still cat-
egorized as having sporadic tumors, as the other three criteria 
for sporadic pheochromocytoma were fulfilled. Pheochro-
mocytomas diagnosed during the evaluation of an incidental 
adrenal mass were categorized as adrenal incidentalomas 
independent of whether patients were categorized as having 
monogenetic etiology or sporadic pheochromocytoma.
Data sources
We searched the PubMed database in April 2017 using the 
words “pheochromocytoma” and “genetic screening”. Only 
English-language literature was used.
Results
The study population (n=41) was initially divided into two 
groups: patients with monogenetic etiology known prior 
to the diagnosis of pheochromocytoma (n=4) and patients 
eligible for genetic screening (n=37).
Genetic screening
Genetic screening results were available in 31 of 37 (83.8%) 
patients (Figure 1). All patients screened for genetic muta-
tions (n=31) had negative screening results. Six patients 
who had not been genetically screened were excluded: one 
patient was initially categorized as having monogenetic 
etiology because of suspected neurofibromatosis type 1 
(NF1) diagnosis. This patient did however have bilateral 
vestibular schwannomas and a genetic screening identified an 
NF2 mutation and thus NF2. Five patients declined genetic 
screening, including four female patients aged 65, 76, 79, 
and 83 years and one male patient aged 52 years at the time 
of diagnosis.
Monogenetic etiology
Four patients carried a germ-line mutation in a gene 
associated with pheochromocytoma. All four patients 
were diagnosed with the genetic mutation prior to the 
diagnosis of pheochromocytoma (Tables 1 and 2). Two 
patients (NF1, n=2) were diagnosed with pheochromo-
cytoma during the evaluation of adrenal incidentalomas, 
and two patients were diagnosed during the surveillance 
program for VHL disease. One patient with monogenetic 
etiology presented a positive family history of pheochro-
mocytoma and VHL disease, whereas the family history 
of pheochromocytoma was negative in the remaining 
three patients. Two patients with monogenetic etiology 
had bilateral pheochromocytomas.
Table 1 Clinical characterization of patients
Overall (n=35) Monogenetic  
etiology (n=4)
Sporadic  
pheochromocytoma (n=31)
Male/female 11/24 3/1 8/23
Age, years, median (range) 56 (12–80) 33 (12–43) 58 (33–80)
Hypertension 21 (60) 3 (75) 18 (58.1)
Diaphoresis 15 (42.9) 0 15 (48.4)
Palpitations 13 (37.1) 2 (50) 11 (35.5)
Abdominal complaints 11 (31.4) 1 (25) 10 (32.3)
Diabetes 10 (28.6) 0 10 (32.3)
Headache 10 (28.6) 1 (25) 9 (29)
Weight loss 7 (20) 0 7 (22.6)
Dizziness 7 (20) 0 7 (22.6)
Nausea/vomiting 5 (14.3) 0 5 (16.1)
No symptoms 4 (11.4) 1 (25) 3 (9.7)
Adrenal incidentaloma 24 (68.6) 2 (50) 22 (71)
Bilateral/multiple tumors 6 (17.1) 2 (50) 4 (12.9)
Positive family history 1 (2.9) 1 (25) 0
Negative family history 34 (97.1) 3 (75) 31 (100)
Notes: Hypertension was defined as systolic pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg and/or antihypertensive treatment. Results given as n (%).
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Sporadic pheochromocytomas
All patients screened for genetic mutation (n=31) had a nega-
tive family history of pheochromocytomas, and metastatic 
disease was not found in any of the patients. Three of 31 
(9.7%) patients screened had bilateral tumors. These patients 
were however categorized as sporadic pheochromocytoma, 
as criteria 1–3 were fulfilled and age was high at time of 
diagnosis (60, 69, and 76 years). One of 31 (3.2%) had local 
recurrences of unilateral pheochromocytomas. This patient 
was 69 years old at diagnosis and 74 years at recurrence. 
A total of 27 of 31 (87.1%) had unilateral pheochromocy-
toma. Three patients, all with unilateral tumors, had genetic 
polymorphisms not previously described as associated with 
pheochromocytoma or tumor syndromes (VHL, n=1; RET, 
n=1; SDHD, n=1).
Adrenal incidentalomas
A total of 24 pheochromocytomas were diagnosed during 
evaluation of adrenal incidentalomas (monogenetic etiology, 
n=2; sporadic pheochromocytoma, n=22). The diameter of 
all adrenal incidentalomas was more than 1 cm.
Age
Patients with monogenetic etiology were all younger than 
45 years at diagnosis of pheochromocytoma (12, 33, 34, 
and 43 years) (Table 1 and Figure 2). Patients with sporadic 
pheochromocytoma had a median age of 58 (range 33–80) 
years, and seven of 31 (22.6%) patients were younger than 
45 years at diagnosis.
Discussion
In the present study, four (11.4%) patients harbored a germ-
line mutation predisposing them to the pheochromocytoma. 
In addition, one patient initially thought to have NF1 was 
diagnosed with NF2. While pheochromocytoma is a rare but 
well-known manifestation in NF1, this has not previously 
been described in NF2. The genetic mutations were all iden-
tified prior to the patients developing pheochromocytoma. 
Screening the remaining subjects with newly diagnosed 
pheochromocytoma did not detect any new mutation-positive 
individuals. The prevalence of genetic mutations in the 
present study was lower than previous studies.11–13 Paragan-
gliomas are reported to be more frequently associated with 
monogenetic aetiology.11,13 The exclusion of these tumors 
could explain the lower prevalence of genetic mutations in 
the present study. A recent systematic review of 31 studies 
and 5,031 patients found the frequency of germ-line muta-
tions in sporadic pheochromocytoma and paraganglioma to 
be approximately 11%–13%.14 Their definition of sporadic 
tumors was very similar to the criteria in the present study, 
including 1) a negative family history of pheochromocytoma 
or paraganglioma, 2) the absence of syndromic features, 3) a 
lack of bilateral disease, and 4) the absence of metastatic 
disease,14 and a recent consensus statement summarized 
gene panels of pheochromocytomas and paragangliomas 
based on current evidence to include ten basic genes (genes 
extensively validated in the literature predominantly asso-
ciated with familial diseases and syndromic features), 15 
extended genes (the basic genes included; genes proven 
to be functionally relevant, but with frequency less than 
1%), and a further 12 comprehensive genes (genes with 
low number of events and limited data) as candidates for 
targeted genetic screening.15
Similar genetic screening programs to the present 
work were performed in several studies in patients with 
pheochromocytoma. Erlic et al found predisposed germ-
line mutations in 188 of 989 (19%) patients with clinical 
presentation of pheochromocytoma and nonsyndromic 
Table 2 Genetic characteristics for patients with monogenetic etiology
Monogenetic etiology, sex,
age at diagnosis (years)
Mutation analysis, 
diagnosis
Syndrome-associated neoplasms Family history, reason for 
referral
VHL, female, 12 VHLc278G→A pGly93Asp, 
VHL disease
Retinoblastoma Mother had pheochromocytoma, 
VHL follow-up
VHL, male, 34 Deletion of exon 3 in the 
VHL gene, VHL disease
Renal cell carcinoma No family history, VHL follow-up
NF1, male, 43 No mutation analysis, NF1 Cutaneous neurofibromas No family history, adrenal 
incidentaloma
NF1, male, 33 No mutation analysis, NF1 Cutaneous neurofibromas No family history, adrenal 
incidentaloma
Abbreviations: VHL, von Hippel–Lindau; NF, neurofibromatosis.
 
R
es
ea
rc
h 
an
d 
Re
po
rts
 in
 U
ro
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
21
-J
ul
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Research and Reports in Urology 2017:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
117
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 pheochromocytoma.12 Mannelli et al found predisposed 
germ-line mutations in 161 of 501 (32.1%) patients with 
pheochromocytoma and/or paraganglioma and in 102 of 341 
(29.9%) patients when paragangliomas were excluded.13 A 
screening for mutations in the RET, VHL, SDHB, and SDHD 
identified predisposed germ-line mutations in 66 of 271 
(24.4%) patients with nonsyndromic pheochromocytoma and 
no family history and in 52 of 241 (21.6%) patients when 
paragangliomas were excluded.11
Rapid advances in genetic screening methods have identi-
fied additional susceptibility genes in pheochromocytoma, 
including SDHA, SDHC, SDHAF2, FH, EGLN1/PHD2, 
KIF1B, HIF2A, TMEM127, and MAX, the latter two with 
frequency of less than 2%.4 The screening of these new 
genes was not included and represents a limitation to the 
present retrospective study. However, several of these genes 
have not yet been fully validated, and information on preva-
lence, penetrance, and phenotype is very limited. Welander 
et al did however establish that 7% of apparently sporadic 
cases carried a germ-line mutation when applying a more 
comprehensive genetic screening panel.16 Future studies 
will illuminate which of the susceptibility genes should be 
included in systematic genetic screening for pheochromo-
cytomas. In the present study, three patients had bilateral 
tumors and one patient had recurrence of unilateral tumor 
but negative genetic screening results. Based on the current 
literature, we think it would be relevant to offer these patients 
new genetic screening in our clinic to investigate for rarer 
genetic causes of pheochromocytoma with a panel of all 
known susceptibility genes.
In the present study, none of the patients with negative 
genetic screening presented with a positive family history of 
pheochromocytoma or other tumors. Still, these patients can 
harbor germ-line mutations in other susceptibility genes.16 
Identifying a genetic predisposition has important implica-
tions for the patient, as it allows for individual surveillance 
programs, genetic counseling, and predictive testing of family 
members. The guidelines for genetic screening are continu-
ously updated, and patients with negative genetic screening 
in the present retrospective study with, eg, adrenergic or 
noradrenergic presentation of pheochromocytomas will in 
future presumably be offered genetic screening with a panel 
of all known susceptibility genes.
The inclusion of patients with pheochromocytoma diag-
nosed during the evaluation of adrenal incidentaloma could 
have affected the prevalence of genetic mutations in the 
present study. A total of 24 of 35 (68.6%) patients included 
were diagnosed due to evaluation of adrenal incidentalomas. 
Our result is consistent with the findings of Motta-Ramirez et 
al, who reviewed records of 335 adrenalectomies and found 
that 19 of 33 (57.6%) pheochromocytomas were adrenal 
incidentalomas.17 In comparison, an autopsy review from 
1981 of 54 autopsy-proven pheochromocytomas found that 
41 of 54 (76%) patients had not been diagnosed with pheo-
chromocytoma while alive.18 Other studies reported adrenal 
incidentalomas in 29 of 192 (15.1%) patients, including 
both pheochromocytoma and paraganglioma19 or pheochro-
mocytomas exclusively found as adrenal incidentalomas in 
15 of 150 (10%) patients.20 In contrast to other studies,19,20 
all patients referred to our department with adrenal inciden-
taloma were systematically screened for pheochromocytoma, 
and this could have increased the observed prevalence of 
pheochromocytomas found as adrenal incidentalomas in the 
present study. In the present study, two patients were catego-
rized as having adrenal incidentaloma, though harboring 
germ-line mutations predisposing to the pheochromocytoma. 
Figure 2 Genetics and age at diagnosis of pheochromocytoma (n=35).
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The patients (both with NF1) were classified as having adre-
nal incidentalomas, as it was not the predisposed germ-line 
mutation or due to surveillance follow-up programs that led 
to further investigation of pheochromocytoma, but because 
of an incidentally discovered adrenal mass. Due to the wider 
use of imaging over the last few years combined with more 
detailed imaging, increased discovery of incidental adrenal 
masses is to be expected, making genetic evaluation of adre-
nal incidentalomas of great importance.21 To our knowledge, 
no studies have evaluated genetic screening of adrenal inci-
dentalomas or incidental pheochromocytomas exclusively.
Due to the limited number of patients, statistical analysis 
was not possible; however, all patients with monogenetic 
etiology were younger than 45 years at diagnosis, which 
supports the view that age <45 years is a predictor of mono-
genetic etiology. Conversely, seven patients with apparently 
sporadic pheochromocytoma were younger than 45 years 
at diagnosis, and of these, two patients had not previously 
described genetic polymorphisms in VHL or RET.
In the present study, two of five patients with bilateral 
tumors had monogenetic etiology (NF1, n=1; VHL, n=1), 
even though this group accounted for only 11.4% of patients 
overall. This result could support bilateral tumors being a 
predictor of monogenetic etiology. Bilateral tumors are more 
often seen in patients with RET mutations.22 As no patients 
with RET mutations were identified, the prevalence of bilat-
eral tumors in our study was expected to be low.
In the present study, we examined genetic variants as 
biomarkers. The use of molecular pathological epidemiology 
(MPE) is emerging and provides an opportunity to investi-
gate the inherent heterogeneity of neoplasms and pathogenic 
processes, such as pheochromocytomas.23 MPE examines 
links between various exposures and the molecular pathology 
of diseases. In pheochromocytomas, MPE could be applied 
specifically to germ-line variants and establish more precise 
genetic screening panels. In the present study, three patients 
with sporadic pheochromocytomas had polymorphisms not 
previously described as associated with pheochromocyto-
mas. In these cases, evaluation of the genetic results could 
benefit from MPE. To our knowledge, no studies have inves-
tigated the potential use of MPE in genetic screening for 
pheochromocytomas.
Strengths and limitations may apply in the present study. 
Our department works as the regional center for patients with 
pheochromocytoma, making the prevalence of monogenetic 
etiology among pheochromocytomas representative of our 
region, covering a population of 1.2 million inhabitants. 
A small population size could lead to higher uncertainty in 
the results presented, and makes it difficult to do statistical 
analysis, which hinders the generalizability of our results. 
As this was a retrospective cohort study, we as investigators 
had limited control of data collection, and we cannot exclude 
the possibility that data are incomplete. Selection bias and 
confounders can occur.
In the present study, the disease causing genetic mutation 
was identified in the patients prior to the diagnosis of pheo-
chromocytoma. Additional studies are needed to determine if 
genetic screening should include all patients diagnosed with 
pheochromocytomas and should be extended to new genes.
Disclosure
These results have previously been presented as a poster at 
the American Urological Association Meeting, May 6–10, 
2016, San Diego, CA, USA. The authors report no conflicts 
of interest in this work.
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